Janumet

Metformin Hydrochloride and Sitagliptin, the active ingredient in Janumet, is a Biguanide / DPP‑4 inhibitor presented as an unspecified strength/tablet for oral use. It treats type 2 diabetes mellitus in adult patients.

GNH USA supplies Janumet as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Janumet is indicated for the management of type 2 diabetes mellitus, a chronic metabolic disorder characterized by hyperglycemia.

Type 2 diabetes mellitus: improves overall glycemic control by lowering fasting and post‑prandial glucose levels. Inadequate response to metformin alone: provides additional glucose‑lowering effect through DPP‑4 inhibition. Patients requiring combination therapy: simplifies regimen with a fixed‑dose tablet containing two complementary agents.

Janumet may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea or abdominal discomfort. - Diarrhea or loose stools. - Headache. - Upper respiratory tract infection symptoms. - Decreased appetite. - Metallic taste.

Serious or Rare Side Effects: - Lactic acidosis (metformin‑related). - Severe hypoglycaemia, especially when combined with insulin or sulfonylureas. - Acute pancreatitis. - Severe allergic reactions such as Stevens‑Johnson syndrome. - Hepatic failure or significant liver enzyme elevation.

Before initiating Janumet, several clinical considerations should be addressed.

Renal function: assess eGFR and avoid use in severe renal impairment. Hepatic function: monitor liver enzymes and avoid in active liver disease. Lactic acidosis risk: contraindicated in patients with conditions predisposing to hypoxia or metabolic acidosis. Pregnancy and lactation: use only if benefits outweigh potential risks. Drug interactions: review concomitant medications that may affect renal clearance or increase hypoglycaemia risk. Store at ambient temperature: keep below 25 °C in the original packaging, protect from moisture and light.

Janumet can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate renal dysfunction, avoid concurrent use. - Insulin or sulfonylureas: increased risk of severe hypoglycaemia. - Cimetidine: may raise metformin plasma concentrations.

Moderate Interactions (Monitor Closely): - Diuretics: can affect renal clearance of metformin. - ACE inhibitors or ARBs: monitor renal function and electrolytes. - Rifampin: may reduce sitagliptin exposure, requiring efficacy assessment.